Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone

被引：0
|
作者：
Oliver Kummer
Felix Hammann
Claudine Moser
Olivier Schaller
Jürgen Drewe
Stephan Krähenbühl
机构：
[1] University Hospital,Division of Clinical Pharmacology and Toxicology, Department of Biomedicine
[2] Mundipharma Medical Company,undefined
来源：
European Journal of Clinical Pharmacology | 2011年 / 67卷
关键词：
Oxycodone; Ketoconazole; Paroxetine; Drug interactions; Pharmacokinetics; Pharmacodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：63 / 71
页数：8
相关论文
共 50 条
  • [21] CYP2D6 Genotype Dependent Oxycodone Metabolism in Postoperative Patients
    Stamer, Ulrike M.
    Zhang, Lan
    Book, Malte
    Lehmann, Lutz E.
    Stuber, Frank
    Musshoff, Frank
    PLOS ONE, 2013, 8 (03):
  • [22] The Effects of Panax Notoginseng Saponins (PNS) on the Activities of 'Rat' CYP2C9, CYP2D6 and CYP3A4
    Iba, Michael M.
    PHYTOTHERAPY RESEARCH, 2014, 28 (01) : 150 - 151
  • [23] The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers
    Schneider, F.
    Stamler, D.
    Bradbury, M. J.
    Loupe, P. S.
    Gordon, M. F.
    Rabinovich-Guilatt, L.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (01) : 11 - 18
  • [24] Influence of CYP2D6 Activity on the Pharmacokinetics and Pharmacodynamics of a Single 20 mg Dose of Ibogaine in Healthy Volunteers
    Glue, Paul
    Winter, Helen
    Garbe, Kira
    Jakobi, Hannah
    Lyudin, Alexander
    Lenagh-Glue, Zoe
    Hung, C. Tak
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (06) : 680 - 687
  • [25] Effect of CYP3A4*1G and CYP3A5*3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects
    Liu, Shuaibing
    Shi, Xiangfen
    Tian, Xin
    Zhang, Xiaojian
    Sun, Zhiyong
    Miao, Liyan
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [26] CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients
    Balyan, Rajiv
    Mecoli, Marc
    Venkatasubramanian, Raja
    Chidambaran, Vidya
    Kamos, Nichole
    Clay, Smokey
    Moore, David L.
    Mavi, Jagroop
    Glover, Chris D.
    Szmuk, Peter
    Vinks, Alexander
    Sadhasivam, Senthilkumar
    PHARMACOGENOMICS, 2017, 18 (04) : 337 - 348
  • [27] Effects of CYP2D6 Genotype on the Pharmacokinetics, Pharmacodynamics, and Safety of Risperidone in Healthy Volunteers
    Novalbos, Jesus
    Lopez-Rodriguez, Rosario
    Roman, Manuel
    Gallego-Sandin, Sonia
    Ochoa, Dolores
    Abad-Santos, Francisco
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2010, 30 (05) : 504 - 511
  • [28] Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug-Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open-Label Studies in Healthy Subjects
    Trivedi, Ashit
    Malik, Fady, I
    Jafarinasabian, Pegah
    Zhang, Hanze
    Flach, Stephen
    Abbasi, Siddique
    Dutta, Sandeep
    Lee, Edward
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (02): : 185 - 193
  • [29] Oxycodone findings and CYP2D6 function in postmortem cases
    Jakobsson, Gerd
    Larsson, Ronja
    Pelle, Lucia
    Kronstrand, Robert
    Green, Henrik
    FORENSIC SCIENCE INTERNATIONAL-GENETICS, 2021, 53
  • [30] The potent mechanism-based inactivation of CYP2D6 and CYP3A4 with fusidic acid in in vivo bioaccumulation
    Lin, Xiu-Xian
    Lian, Guang-Hui
    Xu, Ying
    Zhao, Qing
    Xiao, Jian
    Peng, Shi-Fang
    Xiao, Mei-Fang
    Ouyang, Dong-Sheng
    Tan, Zhi-Rong
    Wang, Yi-Cheng
    Peng, Jing-Bo
    Zhang, Wei
    Chen, Yao
    XENOBIOTICA, 2018, 48 (10) : 999 - 1005
12345